Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04932148

INCremental Dialysis to Improve Health Outcomes in People Starting Haemodialysis (INCH-HD)

The INCH-HD trial will test if incremental HD preserves the quality of life of patients and families and is a safe, practical, cost effective treatment option.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Concord Repatriation General Hospital, Concord, New South Wales, Australia

Loading trial locations.

About this study

Kidney failure is a growing public health problem and fatal unless treated with dialysis or transplantation. Haemodialysis is the most common treatment for kidney failure in Australia and globally. Patients find haemodialysis extremely burdensome due to symptoms like fatigue, pain, cramps and poor quality of life that generally equates to <60% of full health. Furthermore, haemodialysis is associated with an extremely high mortality (<50% survive 5 years), particularly in the first 3-6 months of starting haemodialysis, which is likely linked to the rapid loss of patients' own kidney function when starting haemodialysis abruptly at three sessions/week. Observational studies suggest that starting haemodialysis incrementally at two sessions/ week is associated with lower mortality and better preservation of patients' remaining kidney function while offering many patient-important advantages, including dialysis free time and ability to work. However, robust evidence to recommend this incremental approach is lacking.

The INCH-HD study is an investigator-initiated, international, multicentre, prospective, adaptive, randomised, open-label, parallel group, non-inferiority trial. The primary objective of the study is to demonstrate whether incremental HD is non-inferior to conventional HD for the patient-important outcome of quality of life measured using Kidney-specific component of the Kidney Disease Quality of Life - Short Form measurement (KDQOL-SF) at 6 months from dialysis commencement.

The study will recruit a total of 372 participants across HD centres in Australia, and Canada. The outcomes of this trial will will provide urgently needed high quality evidence on whether starting haemodialysis incrementally at two sessions/week compared to the conventional three sessions/week can safely reduce the physical, financial and quality-of life burden on patients, lower early mortality rates and slow loss of kidney function while increasing haemodialysis capacity and reducing costs.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (≥ 18 years of age) and
  • Commencing HD as their initial dialysis therapy and
  • Able to give informed consent

Exclusion criteria

  • Urine output <0.5Litres/day
  • Unlikely to be on HD for ≥1 year.

Treatment and study plan

Incremental HD

Other

Starting haemodialysis at twice weekly frequency

Conventional HD

Other

Starting haemodialysis at thrice weekly frequency

Primary outcomes

  1. Heath related quality of life

    Time frame: 6 months

    This will be measured using Kidney-specific component (KSC) of the Kidney Disease Quality of Life Short Form (KDQOL-SF) V1.3 questionnaire. The KSC is the mean of the 11 domains of the kidney-disease specific items of KDQOL-SF. Scores are transformed onto a 0-100 range, where a higher score reflects a better quality of life.

Secondary outcomes

  1. Residual kidney function (RKF)

    Time frame: Baseline, 3, 6, 12 and 18 months

    Calculated as (creatinine clearance + kidney urea clearance) divided by 2 then corrected for body surface area using the DuBois method (0.20247 x (height in centimetres x 0.725) x (weight in kilograms x 0.425).

    Expressed as millilitres per minute (ml/min). Expected range 1 ml/min to 20 ml/min, where lower values indicate worse kidney function.

  2. Healthcare resource utilisation

    Time frame: Baseline to 18 months

    Healthcare resource use over 18 months using linked data and patient monthly calendars

  3. Healthcare costs

    Time frame: Baseline to 18 months

    Healthcare costs over 18 months using linked data and patient monthly calendars

  4. Heath related quality of life using Kidney Disease Quality of Life Short Form (KSQOL-SF) questionnaire

    Time frame: Baseline, 3, 6, 9, 12, 15 and 18 months

    Heath-related quality of life will be measured using Kidney-specific component (KSC) of the Kidney Disease Quality of Life Short Form (KDQOL-SF) V1.3 questionnaire. The KSC is the mean of the 11 domains of the kidney-disease specific items of KDQOL-SF. Scores are transformed onto a 0-100 range, where a higher score reflects a better quality of life.

  5. Heath related quality of life using EuroQol 5-dimension 5-level (EQ-5D-5L) questionnaire

    Time frame: Baseline, monthly to 18 months

    Heath-related quality of life will be measured using EuroQol 5 Domain 5 Level (EQ-5D-5L) questionnaire. EQ-5D has descriptive and visual analogue scale (VAS). Descriptive system consists of five dimensions mobility, self-care, usual activities, pain/discomfort and anxiety/depression. VAS records patient's self-rated health on vertical visual analogue scale with endpoints best to worst health with 0 being worst and 100 being best health.

  6. Incidence of all-cause mortality

    Time frame: Baseline to 18 months

    Incidence of all-cause mortality up to 18 months

  7. Time to major cardiovascular event (MACE)

    Time frame: Baseline to 18 months

    Time to first major cardiovascular event (MACE) up to 18 months

  8. Number of non-elective hospital admissions

    Time frame: Baseline to 18 months

    Number of non-elective hospital admissions up to 18 months

  9. Total hospital days

    Time frame: Baseline to 18 months

    Total hospital days up to 18 months

  10. Time to death

    Time frame: Baseline to 18 months

    Time to death up to 18 months

  11. Number of hospital admissions

    Time frame: Baseline to 18 months

    Number of hospital admissions up to 18 months

  12. Adverse events and side-effects

    Time frame: Baseline to 18 months

    This will include episodes of hyperkalaemia, extra dialysis sessions for fluid overload, number of vascular access complications

  13. Symptom scores

    Time frame: Baseline, 3, 6, 9, 12, 15 and 18 months

    This will be measured using change in the physical and mental component summaries of the Kidney Disease Quality of Life Short Form (KDQOL-SF) V1.3 questionnaire. This is scored using the mean of the physical and mental components of the KDQOL-SF. Scores are transformed onto a 0-100 range, where a higher score reflects a better quality of life.

  14. Fatigue

    Time frame: Baseline, 3, 6, 9, 12, 15 and 18 months

    This will be measured using the Standardised Outcomes in Nephrology-Haemodialysis (SONG-HD) Fatigue questionnaire. The SONG-HD Fatigue measure consists of three items that assess the effect of fatigue on life participation, tiredness, and level of energy. The overall score for fatigue is obtained by summing the responses across the three questions, resulting in a scale ranging from zero (no fatigue) to nine (maximum fatigue).

  15. Nutritional Status

    Time frame: Baseline, 6, 12 and 18 months

    This will be measured using the Subjective Global Assessment (SGA) of nutrition which is scored as proportion of well nourished (A) versus malnourished (B or C). A (well nourished), B (mildly-moderately malnourished), C (Severely malnourished)

  16. Vascular access

    Time frame: Baseline to 18 months

    This will be measured as mumber of functional vascular access interventions required per patient per year to enable and /or maintain vascular access for HD per patient-year

Other outcomes

  1. Patient lifestyle and wellbeing

    Time frame: Baseline, 3, 6, 9, 12, 15 and 18 months

    This will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) SF 4a (Ability to Participate in Social Roles and Activities and Satisfaction with Social Roles and Activities)

  2. Time to event

    Time frame: Baseline to 18 months

    Time to trigger condition being met in Incremental HD patients (date the trigger condition/s were met) and subsequent time to transition to 3x/week HD

Study contacts

Contact information is provided by the study sponsor or research team.

Lisan Mulvey

CONTACT

[email protected]

+61 417 690 237

Sponsors and collaborators

Lead sponsor

The University of Queensland

Other

Collaborators

  • Canadian Institutes of Health Research (CIHR)
  • Medical Research Future Fund
  • Queensland Health

Registry information

Official study title

The INCremental Dialysis to Improve Health Outcomes in People Starting Haemodialysis (INCH-HD) Study: a Randomised Controlled Trial

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Jun 18, 2021
Registry last updated
May 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.